LoA Update: Chengdu Kanghong Pharmaceuticals’ Phase III ophthalmic agent drops 7 points in AMD after trial stop
The likelihood of approval (LoA) of Chengdu Kanghong Pharmaceuticals’ (SHE:002773) Phase III conbercept in neovascular age-related macular degeneration (AMD) dropped…